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Background: Validated guidelines to manage low-density lipoprotein (LDL)-cholesterol 
are utilized inconsistently or not at all even though their application lowers the incidence of 
  coronary events. New approaches are needed, therefore, to implement these guidelines in 
everyday practice.
Methods and results: We compared an automated method for applying The National 
Cholesterol Education Panel (NCEP) guidelines with results from routine care for managing 
LDL-cholesterol. The automated method comprised computerized history-taking and analysis 
of historical data without physician input. Results from routine care were determined for 213 
unselected patients and compared with results from interviews of the same 213 patients by a 
computerized history-taking program. Data extracted from hospital charts showed that routine 
care typically did not collect sufficient information to stratify risk and assign treatment targets 
for LDL-cholesterol and that there were inconsistencies in identifying patients with normal 
or elevated levels of LDL-cholesterol in relation to risk. The computerized interview program 
outperformed routine care in collecting historical data relevant to stratifying risk, assigning 
treatment targets, and clarifying the presence of hypercholesterolemia relative to risk.
Conclusions: Computerized history-taking coupled with automated analysis of the clinical 
data can outperform routine medical care in applying NCEP guidelines for stratifying risk and 
identifying patients with hypercholesterolemia in relation to risk.
Keywords: dyslipidemia, coronary disease, prevention, management, computerized-history 
taking
Coronary artery disease is the leading cause of death in the developed world.1 
  Fortunately, risk for coronary events can be mitigated by lowering concentrations 
of low-density lipoprotein (LDL)-cholesterol that have been shown in large-scale 
  epidemiologic studies to enhance risk for an event.2–8 Despite, however, the high inci-
dence of a lethal event and evidence that its risk can be decreased, there is poor adher-
ence in everyday practice to guidelines for managing dyslipidemia or elevated levels 
of LDL-cholesterol in order to decrease risk for coronary events.9–16 Kuklina et al16 
suggest that general failure to diminish risk for coronary events by applying National 
Cholesterol   Education Program (NCEP) guidelines to reduce LDL-cholesterol6 reflects 
the complexity of the guidelines. A recent editorial in the Journal of the American 
Medical Association characterized the guidelines as “… cumbersome and a challenge 
to implement”.17   Several ideas have been proposed to simplify guidelines for manag-
ing LDL-cholesterol, but most retain assessment of risk from sets of detailed clinical 
data.17–19 Given the relatively large number of patients who must be treated to prevent a 
single coronary event,20–22 it is reasonable to posit that more not less knowledge needs Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to be applied to assessing risk. More medical knowledge, of 
course, will increase the complexity of risk-assessment in 
everyday practice; and inevitable growth in the classes of 
drugs that lower LDL-cholesterol will increase further the 
complexity of treatment decisions.23 Simplifying current 
guidelines to get better clinical outcomes is unlikely, there-
fore, to be effective in the long-run. We thus need alternative 
mechanisms to enhance patient outcomes through adherence 
to validated clinical guidelines.
Computers can be programmed to acquire the detailed 
historical data for assessing risk for coronary events,24–26 to 
score the historical factors according to any risk equation, and 
to output the data for interpretation and review by the health 
care provider. So in theory, a properly designed computer 
program interacting directly with patients should be able to 
collect primary data for applying NCEP guidelines, interpret 
these data accurately to assign level of risk, and recommend 
treatment in the context of risk-related targets for treating 
LDL-cholesterol. This is an attractive area for study because 
of the medical significance of coronary artery events and 
because there are effective treatments to reduce risk for an 
event that go largely unused.9–16 Moreover, clinical details 
in the patient’s medical history are the key data elements for 
implementing the NCEP guidelines; and the guidelines are 
clear-cut and easily formalized as machine-readable code. 
We have tested these ideas in the current work and report here 
on the use of computing to assess risk for coronary events 
and set therapeutic targets for LDL-cholesterol, according 
to NCEP guidelines, through direct interaction between 
computers and patients in the absence of inputs by health 
care providers. Comparisons of outputs from the computer 
program used in this way with charts for usual care show that 
the computer program outperforms physicians in the tasks 
of data collection to assess risk, assigning risk according to 
NCEP guidelines, and diagnosing dyslipidemia on the basis 
of the guidelines.
Methods
software and deployment
The design principles, ownership, medical content, and 
deployment of the software comprising the CLEOS® 
  program are presented in detail elsewhere.26 Questions used 
to interview patients were formatted by experienced clini-
cians in different domains of medicine and were based on 
standard text book formulations for acquiring information 
about the presence and absence of specific sets of symptoms, 
relationships between symptoms according to principles of 
pathophysiology, clinically relevant information related to 
risks for disease, prior and present treatments for disease, 
social history, and family history. As shown in detail in 
Zakim et al,26 questions were arranged as decision graphs 
based on pathophysiologies for diseases of different organ 
systems.
Computerized history-taking in the present work was not 
focused on data elements relevant only to risks for coronary 
events. Complete medical histories were obtained from all 
patients interviewed. Data elements relevant to application of 
NCEP guidelines were evaluated automatically by an internal 
inference engine to output findings for risk level in relation 
to targets for treating LDL-cholesterol.
Patients
Patients were in-patients in the departments of Internal 
Medicine and Cardiology at the Robert Bosch Krankenhaus, 
Stuttgart, Germany. Ages of patients ranged from 20 to 84 
with a median of 51 years. Males comprised 54% of the study 
group. A single study nurse was responsible for recruiting 
patients. The nurse had no prior knowledge of a patient’s 
primary and secondary diagnoses or the purpose of data col-
lection and eventual data analysis. The study nurse did not 
record demographic data, admitting diagnoses, or severity 
of current illness for any patient entered in the study or for 
patients who declined to participate. Sixteen different physi-
cians provided routine care for the patients for whom data 
are reported in this work. Patients were not recruited on the 
basis of physicians responsible for in-hospital care, gender, 
age, or prior experience with computers. None of the authors 
was involved in recruiting patients for the interview nor did 
any hospital physicians participate in recruitment. The criteria 
for inclusion in this study were patient-consent for interview 
by the CLEOS® program and reading knowledge of German 
or English. No patient who agreed to participate had to be 
excluded because of inability to read one of these languages. 
Ten patients declined interview by the computer program. 
Data for these patients are not included in this study. All 
patients who agreed to participate in the program entered 
a complete medical history via the computerized interview. 
Ethics approval for this study was waived by the ethical board 
of the University of Tuebingen.
Data collection
Standard physician histories, designated here as routine 
care, were taken on admission by each patient’s responsible 
physician. Patients subsequently self-interviewed using 
the CLEOS® program,26 which acquired a present illness, 
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social history, and family history. We note that this study 
was designed with a single cohort of patients. Clinical data 
in the chart for routine care for each patient in this study 
were compared with clinical data from computer-generated 
outputs of the CLEOS® program for the same patient. All 
patients were German-speaking and were interviewed by the 
German-language version of the CLEOS® program. Patients 
self-interviewed on their ward or the office of the study 
nurse after routine history-taking was completed by their 
responsible physician and when interviews by the CLEOS® 
program did not interfere with other aspects of routine care. 
The computerized interview was conducted usually on the 
same day or within 2 days of the admission history for routine 
care. Reports from CLEOS® interviews were not made avail-
able to physicians caring for patients. No treatment decisions 
were undertaken or reviewed because of data collected by 
the CLEOS® interview.
Data extraction from charts  
for routine care
The data fields extracted from charts were those used 
by NCEP guidelines to characterize risk for coronary 
events, for example, the presence of diabetes, history 
of angina, history of peripheral vascular disease, smok-
ing, hypertension, according to a scale of high, mod-
erate, or low risk and assignment to target levels of 
LDL-cholesterol #100 mg/dL (high risk), #130 mg/dL 
(moderate risk), or #160 mg/dL (low risk).1 Charts for 
routine care were read to tabulate the presence or absence 
of relevant data fields, for the presence of explicit statements 
of level of risk and target levels of LDL-cholesterol, and to 
tabulate entries about present or past treatment to reduce 
LDL-cholesterol. Review and data extraction extended across 
the chart for the entire period of each patient’s   hospitalization. 
In addition, all discharge letters to referring physicians were 
reviewed to search for clinically relevant data possibly not 
recorded in the hospital chart but known to a patient’s respon-
sible physician. Tabulations of data for routine care did not 
discriminate between data obtained from a chart and data 
obtained from a discharge letter. Since no chart for routine 
care contained statements about level of risk or targets for 
LDL-cholesterol (See results), evaluation of charts for routine 
care for consistency between clinical data and assignment of 
level of risk had no meaning. We did not plan a priori to deter-
mine whether a patient at moderate risk by historical data 
was at high enough risk to warrant a target of #100 mg/dL 
on the basis of combined clinical and laboratory data. This 
decision was made because the computer-based program did 
not include on-line acquisition of laboratory data at the time 
computer-based interviews were conducted. As indicated in 
the results, the general absence of sufficient data for assign-
ing patients to a level of moderate risk by historical criteria 
made meaningless any subclassification within this group. 
Values of LDL-cholesterol were measured at the Robert 
Bosch Krankenhaus during the hospitalization for which 
the chart for routine care and the CLEOS® interview were 
generated.
Charts for routine care were extracted independently by 
CF, NB, and MDA. Fifty charts at random were reviewed 
independently by both CF and NB. No discrepancies were 
found between reviewers in this subset of 50 charts. Data 
tabulated from charts for routine care were analyzed by DZ 
to assign a level of risk and a target for LDL-cholesterol 
according to NCEP guidelines.
Data extraction from  
computerized-history-taking
The CLEOS® program collects historical information 
by direct interview of the patient and automatically ana-
lyzes these data to stratify risk and output a target for 
LDL-  cholesterol appropriate for level of risk. Figure 1 
is an example of an output relevant to NCEP guidelines 
for LDL-cholesterol. Outputs from the CLEOS® program 
were read to tabulate target levels for LDL-cholesterol 
and were examined patient-by-patient for consistency 
between assigned targets for LDL-cholesterol and recorded 
clinical data for assigning the target according to the NCEP 
  guidelines. Since, as mentioned above, the version of the 
CLEOS® program used in the current work did not include 
online acquisition of laboratory fields, NCEP guidelines 
applied to data analysis excluded laboratory values for total 
cholesterol and high-density lipoprotein (HDL)-cholesterol 
for either routine care or computer history. Extraction of 
CLEOS® records was done by DZ.
Results
History-taking and decision-making 
to stratify risk for coronary events 
according to nceP guidelines
Two tasks must be completed to mitigate risk for coronary 
events through managing concentrations of LDL-cholesterol 
according to NCEP guidelines. The first is collecting the clini-
cal data required by the guidelines for stratifying risk as high 
(LDL-cholesterol target of #100 mg/dL), moderate (LDL-
cholesterol target of #130 mg/dL), or low   (LDL-cholesterol Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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target of #160 mg/dL). The second is assigning a target 
for LDL-cholesterol that is appropriate to the level of risk 
identified by the clinical data.
Two hundred thirteen medical records for routine care 
and CLEOS® interviews for the same set of 213 unselected 
patients were reviewed to evaluate performance of these 
tasks by physicians and the CLEOS® program. Results 
are summarized in Table 1. Review of charts for routine 
care   demonstrated insufficient clinical data to assign a level 
of risk in 70% of patients and an absence of explicit state-
ments for level of risk in all charts. Clinical data collected 
during routine care were sufficient to assign any level of 
risk for coronary events in 64 patients, of whom 57 could be 
assigned to high risk. Of the 149 charts for routine care with 
insufficient data to assign any level of risk, it was possible to 
exclude high risk for coronary events in only 12 patients.
The CLEOS® program identified 81 patients at high risk 
for a coronary event on the basis of history. Differences in 
the number of high-risk patients recorded in charts for routine 
care and CLEOS® were due to better case finding by CLEOS® 
for patients with past histories of bypass surgery, angioplasty, 
myocardial infarction, and peripheral vascular disease.
The group of high-risk patients identified by CLEOS® 
interviews does not include 6 patients at high risk by data 
in charts for routine care on the basis of transient ischemic 
attacks (1 patient), coronary artery disease (1 patient), and 
diabetes (4 patients). For the patient with transient ischemic 
attacks according to the chart for routine care, the CLEOS® 
program reported this patient had a moderate risk for a coro-
nary event because of age and hypertension and assigned a 
target level for LDL-cholesterol of 130 mg/dL. The output 
of the CLEOS® program for this patient qualified risk assign-
ment with an alert to reclassify the patient to high risk if the 
patient’s neurologic symptoms were attributable to transient 
ischemic attacks. For the patient with coronary artery disease 
according to the chart for routine care, the CLEOS® program 
assigned the patient to the group with moderate risk with 
an alert to reclassify to high risk if the patient’s chest pain 
was verified as angina. These 2 patients are reported for 
the CLEOS® data as instances of a target of 130 mg/dL to 
be consistent with reporting conclusions derived from the 
CLEOS® interview only on the basis of historical data avail-
able at admission. Including these patients, the CLEOS® chart 
identified all patients at high risk in data in charts for routine 
care except for a subgroup with diabetes.
Four patients with diabetes, according to the chart for 
routine care or discharge letter, answered they did not have 
diabetes when asked this question during the CLEOS® 
interview. Assignment of these patients to LDL-cholesterol 
targets of 130 mg/dL was incorrect for failure in data collec-
tion but was consistent internally with the data collected by 
CLEOS®. These patients are cited in Table 1 as instances of 
errors/omissions in data collection by the CLEOS®   program. 
The false negative findings for diabetes were detected by 
monitoring of discrepancies between routine care and history-
taking by CLEOS® in the time before data analysis related 
to coronary risk was undertaken. These failures to detect the 
presence of diabetes with the CLEOS® interview occurred 
with a question that queried the absence/presence of diabetes 
as 1 line in a questionnaire. We concluded that the question 
about prior diagnosis of diabetes was not read carefully in 
this format and modified the query about   presence/absence 
of diabetes as the only question on the page. Subsequent 
to this change, the CLEOS® program properly identified 
11 diabetics, all of whom could be identified as diabetic 
in charts for routine care or discharge letters on the basis 
of explicit statements related to medical history, elevated 
fasting blood sugar, and/or administration in hospital of 
hypoglycemic agents.
The group of high-risk patients identified by CLEOS® 
interview but not routine care included 4 with historical evi-
dence of intermittent claudication in the absence of diabetes, 
prior coronary events, or other evidence for atherosclerotic 
disease. Review of the primary data collected by CLEOS® 
for these patients confirmed that intermittent claudication 
was the best working diagnosis to explain effort-induced leg 
pain relieved promptly by rest. Review of the primary data 
in the output of the computerized interview of these patients 
• On the basis of historical data, the LDL-cholesterol <130 is minimal target in
this patient because of age and active smoking. Further reduction of risk in
patients with this risk profile is achieved with LDL-cholesterol <=100. Patient
should stop smoking, but this will not alter current target value for LDL
cholesterol. The patient’s risk for CAD/stroke has to be stratified further by
systolic BP, total cholesterol and HDL-cholesterol. Once these are entered, the
program will calculate whether risk for CAD =>20% over 10 years, in which case
maximum preventive benefit is achieved at LDL-cholesterol =<70. 
Figure 1 sample text of output by the cLeOs® program for reporting stratification of risk for a coronary event and target for treating LDL-cholesterol.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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did not support alternative diagnoses of spinal stenosis 
or venous insufficiency. Obviously, however, symptoms 
compatible with intermittent claudication require objective 
support through physical examination and objective test-
ing before undertaking a management decision to treat the 
affected patients as at high risk for coronary events.   Historical 
evidence for claudication in charts for routine care was not 
mentioned as positive or negative for these patients. The 
charts for routine care lacked physical examination data for 
the presence or absence of peripheral pulses or other signs 
of peripheral vascular insufficiency. No laboratory testing 
was undertaken in these patients to confirm the presence of 
intermittent claudication. The diagnosis of intermittent clau-
dication thus was not confirmed objectively in these patients. 
The value of CLEOS® for care of these patients was in iden-
tifying an important rule-out diagnosis for management of 
coronary risk, which was missed by routine care.
The CLEOS® program failed to report an explicit target 
for LDL-cholesterol in 4 patients. The clinical data col-
lected by CLEOS® for these 4 patients nevertheless correctly 
excluded high risk for coronary disease and were sufficient 
to assign targets for LDL-cholesterol of 130 or 160 mg/dL. 
Failure to report a target for these 4 patients was traced 
to logic errors in rules triggering appropriate outputs of a 
  narrative text.
Diagnosis of hypercholesterolemia 
according to guidelines and treatment 
decisions
Physicians, to save time, do not always document the evi-
dence for clinical decisions, for example, that a patient is or 
is not at high risk for a coronary event. It is significant in 
this context that discharge letters but not the   corresponding 
charts cited 39 patients as hypercholesterolemic at the 
time of discharge. Comparison of concentrations of LDL-
cholesterol during hospitalization with target levels for 
LDL-cholesterol determined from data collected by CLEOS® 
indicated, however, that 21 of the patients diagnosed with 
hypercholesterolemia were at or below target levels for LDL-
cholesterol, and no measurement of cholesterol was available 
in 4 others. By contrast, levels of LDL-cholesterol in excess 
of targets according to NCEP guidelines were not recognized 
in about 70% of patients with hypercholesterolemia. Statin 
therapy was initiated during hospitalization in 22 patients, 
based on notes in charts for routine care. Fourteen of these 
patients were not hypercholesterolemic by NCEP criteria.
Discussion
This work confirms poor adherence to NCEP guidelines 
for managing elevated levels of LDL-cholesterol.9–16 
van Wyk et al27 have shown, in this regard, that electronic 
alerts keyed to data in an electronic medical record can 
improve adherence to the guidelines. The current work 
extends the findings in the literature in general and the work 
of van Wyk et al27 in particular by indicating that failure 
to interpret or understand clinical data collected from the 
patient is only part of the problem of compliance with NCEP 
guidelines. There also is frequent failure to acquire sufficient 
clinical data for assigning level of risk according to NCEP 
guidelines. This is important to recognize considering recent 
thinking of how to improve outcomes for people at risk for 
coronary events. One suggestion, for example, is to treat with 
statins everyone at greater than low risk.17 Although appar-
ently simple, this guideline is unlikely to work in practice 
because, as the current work illustrates, clinical data are typi-
cally inadequate for assessing risk. In the current work, for 
Table 1 comparison of assigned levels of risk for coronary disease and completeness of data for assigning risk for clinical data 
extracted from charts for routine care and assignments of risk output automatically by the cLeOs® program for the same set of 
213 patients
Level of risk Assigned from charts 
for routine care
Output in 
CLEOS® report
High risk with target #100 57 81
Target #130 3 54
Target #160 4 74
Data sufficient to exclude high risk 12 128
explicit statement of target for LDL-cholesterol 0 209
Data sufficient to assign risk but error in interpretation nA 4
errors/omissions in data collection 146 4
Notes: Assignments of risk for data from routine charts are based on analysis of primary clinical data extracted from these charts. This was necessary because no chart for 
routine care contained an assignment of risk. Assignment of risk for data obtained by the cLeOs® program are the treatment targets assigned through automated analysis by 
cLeOs® of the clinical data collected by the program.
Abbrevation: nA, not applicable.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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example, there were insufficient clinical data for classifying 
patients at high or moderate risk.
The present work illustrates an alternative to simplify-
ing or even dumbing-down guidelines for managing LDL-
cholesterol. The present work shows that a computerized 
history-taking program interacting directly with patients can 
collect sufficient clinical data to implement NCEP guidelines 
for assigning risk and that combined computerized data col-
lection and automatic, computerized data analysis within 
a single technology, enables automated computer-based 
analysis of the historical data in the context of established 
guidelines to output findings as simple explicit statements 
of risk levels and targets for managing LDL-cholesterol 
 ( Figure 1). These simple statements about target levels 
can be compared directly with measured levels of LDL-
cholesterol to determine whether or not the patient has 
LDL-cholesterol that is elevated for their risk of coronary 
events.   History-taking and analysis in this way can not only 
save physician time for collecting data, it can also outperform 
physicians in this important facet of practice. It also makes it 
possible to incorporate refinements in predictive algorithms 
that will make it harder for people but not computers to use 
enhanced guidelines.
The version of CLEOS® used in the current work did 
not incorporate laboratory and physical findings to further 
stratify patients with a target level of 130 mg/dL or to factor 
concentrations of HDL-cholesterol into determination of risk; 
therefore it did not utilize all features of NCEP guidelines. 
There were no instances, however, in which physicians used 
these features of the guidelines; and compared with teach-
ing to ensure efficient use of these features by physicians 
in everyday practice, these features can be “taught” easily 
to a program like CLEOS®, as can functionality for treat-
ment strategies appropriate for individual patients. Further 
clinical benefit from the approach used in this work is rapid, 
inexpensive distribution of the primary data and analytic 
conclusions via the Internet to any physician caring for a 
patient interviewed by the CLEOS® program. The program 
also leaves an indelible trail of what it did and did not do 
in collecting and analyzing the clinical information, which 
facilitates finding and correcting systematic errors.
Computer-based identification  
and management of risk for coronary 
events has general applicability
Patients in this study were older, had a higher burden of 
disease than patients in a community setting, and were 
hospitalized at a single institution. Depending on the 
patient population and expertise of physicians, there will be 
  differences in the extent of discrepancies between routine 
care and results from the CLEOS® program in the context of 
managing LDL-cholesterol. We would expect no differences 
between routine care and application of the CLEOS® program 
for a study carried out in a specialized clinic for diagnosis 
and management of dyslipidemia. Relatively few patients at 
risk for coronary events are seen in such specialized clinics, 
however; and results for routine care in the present work 
accord with those reported in the literature.9–16,27 The evidence 
indicates, therefore, that the results in the current work have 
general applicability.
Differences in case-finding between 
routine care and the cLeOs® program 
cannot be attributed to false positive 
findings
Patients make mistakes during the computerized interview 
because they do not understand the question or they make an 
accidental, unintended selection of an answer. The study nurse 
observed patients realizing they made an erroneous entry, as 
follow-up questions were asked and correcting mistakes by 
using the program’s back button. It is important to mention 
in this regard, that risk factors for coronary events were not 
determined as positive because of answers to single questions 
but by a set of consistent answers to a line of questioning 
determined by established pathophysiology. The chance of 
false negative findings with CLEOS® is more likely than the 
chance of false positives because a positive answer about the 
presence of symptoms or a prior diagnosis opens a line of 
questions, whereas a negative answer can be at the end of a 
line of questions. Given that false positive findings would be 
generated not by deliberate falsification but by random error, 
the absence of a significant rate of false negatives would be 
evidence against a significant rate of false positives. We do not 
see in the present data evidence for false negative findings that 
cannot be traced to errors in logic as opposed to data-capture, 
except for the consistent failure to identify the occurrence of 
diabetes. This error appears to have been caused by poor design 
of the page querying a prior diagnosis of diabetes.
Conclusions
A computerized history-taking program coupled with auto-
mated analysis of clinical data collected by direct interview 
of patients can outperform routine medical care for strati-
fying risk for coronary events that is mitigated by manag-
ing levels of LDL-cholesterol, for identifying treatment 
targets in individual patients, for identifying patients with Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  hypercholesterolemia in relation to risk, for selecting patients 
in whom active management of levels of LDL-cholesterol 
is indicated, and for identifying statin-induced adverse drug 
effects past and present.
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